ESTRO 2024 - Abstract Book

S1685

Clinical - Lung

ESTRO 2024

Initial findings of PREHABS indicate that it is feasible to embed routine dietetic review into the radical RT lung pathway and that patients are accepting of dietetic intervention. Preliminary findings support the recommendation for a specialist thoracic dietitian to reduce inequalities in nutritional care for patients with lung cancer by mirroring the well-established dietetic services in place for the H&N and Upper GI patient populations.

Keywords: Lung Cancer, Malnutrition, Dietitian

References:

1 Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiotherapy and Oncology 2003;67(2):213-20.

2 Santarpia L, Contaldo F, Pasanisi F. Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle 2011;2(1):27-35.

3 Barthelemy N, Streel S, Donneau AF, Coucke P, Albert A, Guillaume M. Screening for malnutrition in lung cancer patients undergoing radiotherapy. Supportive care in cancer 2014;22:1531-6.

4 Nourissat A, Vasson M, Merrouche Y, Bouteloup C, Goutte M, Mille D, Jacquin J, Collard O, Michaud P, Chauvin F. Relationship between nutritional status and quality of life. European Journal of Cancer 2008; 44 (9): 238-1242.

5 ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition 40 (2021) 2898-2913.

1633

Digital Poster

Thirteen years experience of ultra-central lung SBRT in Hong Kong - a single institution study

Justin K.W Ng, Michael T.Y Kam, Janet Q.J Du, Edwin C.Y Wong, Ken K.S Wong, Rebecca M.W Yeung

Pamela Youde Nethersole Eastern Hospital, Clinical Oncology, Chai Wan, Hong Kong

Purpose/Objective:

Use of Stereotactic Body Radiation Therapy (SBRT) for ultra-central lung tumours remains controversial given the proximity of lesions to critical organs at risk (OAR), raising concerns for potential severe toxicity. Outcomes of ultra central lung SBRT have been reported mainly in Western populations with heterogeneity in dose prescriptions and OAR constraints and prospective studies are still ongoing. In this study, we report real-world outcomes of ultra central lung tumours treated with SBRT at a major cancer center in Hong Kong.

Material/Methods:

A retrospective analysis of patients with primary or oligometastatic ultra-central lung tumours treated with SBRT from 2009 to 2022 was conducted